HRT Does Not Cause Breast Cancer
Bioidentical Hormones Beneficial After Hysterectomy
Bioidentical Hormones Beneficial for Breast Cancer Survivors
The Safety of Transdermal Estrogen Part One
The Safety of Transdermal Estrogen Part Two
Links and references
1) http://www.cbsnews.com/news/bioidenticals-no-safer-than-other-hormone-replacement-therapy/ By Michelle Castillo CBS News October 29, 2013, 7: 16 AM Bioidenticals no safer than other hormone replacement therapy
2) http://www.ncbi.nlm.nih.gov/
Altern Med Rev. 1999 Aug;4(4):266-70. Comparative measurements of serum
estriol, estradiol, and estrone in non-pregnant, premenopausal women; a
preliminary investigation. Wright JV, Schliesman B, Robinson L. Source
Tahoma Clinic, 515 W. Harrison, Ste. 200, Kent, WA 98031, USA.
The fractionated estrogen concentration data from the population of 26 women
shows that the estriol in every case was at least three times as great
as the concentration of estradiol and estrone combined. With estriol
circulating at nearly 10 times the concentration of estrone and
estradiol, it appears at least a possibility that there must be unknown
significant biological activity for this "weaker"
hormone.
3)http://www.ncbi.nlm.nih.gov/pubmed/10714912
Maturitas. 2000 Feb 15;34(2):169-77. Efficacy and safety of oral
estriol for managing postmenopausal symptoms. Takahashi K, Manabe A,
Okada M, Kurioka H, Kanasaki H, Miyazaki K.
Source Department of Obstetrics and Gynecology, Shimane Medical University, Izumo, Japan.
to assess the therapeutic efficacy and safety of oral estriol for the treatment of climacteric symptoms in postmenopausal women.
METHODS: 68 postmenopausal women with climacteric symptoms received
oral estriol, 2 mg/day, daily for 12 months. We evaluated the degree of
climacteric complaints with estriol therapy; serum levels of
gonadotropins, estradiol (E2) and lipids; biochemical markers of bone
metabolism; blood pressure; and side effects both at baseline and during
treatment. Climacteric symptoms were assessed according to the
menopausal index (MI), a version of the Kupperman index that had been
modified for Japanese women.
RESULTS: oral estriol therapy significantly reduced total MI scores.
The greatest relief was noted for hot flushes, night sweats, and
insomnia. Estriol treatment significantly lowered serum follicle
stimulating hormone (FSH) and luteinizing hormone (LH) concentrations
but did not affect any of the other parameters (lipids, bone, liver and
blood pressure) during the study period. Slightly vaginal bleeding
occurred in 14.3% of those who underwent natural menopausal women.
Histologic evaluation of the endometrium and ultrasound assessment of
the breasts following 12 months of estriol treatment found normal
results in all women.
CONCLUSION: Estriol is a safe and effective alternative for relieving climacteric symptoms in postmenopausal Japanese women.
4) http://www.ncbi.nlm.nih.gov/
Estrogen Treatment in Multiple Sclerosis -- Stefan M Gold and Rhonda R Voskuhl*
Multiple Sclerosis Program, Department of Neurology, and Cousins Center,
Geffen School of Medicine, University of California Los Angeles, U.S.A.
*Corresponding author, Address: Neurosci Res Bldg 1, 4th Floor, 635 Charles E Young Dr S, Los Angeles, CA 90095, U.S.A
Quantitatively, estriol is a very weak estrogen and preferentially binds ERß versus ERa (61--64). This is important since binding of each ER can result in opposite effects on transcription (65). Estriol has been accepted as the safest of the three estrogens in reviews dating from the 1970s to the 2000s (66--69). It has been used extensively in Europe and Asia for the treatment of menopausal symptoms (70--77) and, unlike 17ß-estradiol, causes minimal uterine endometrial proliferation (69, 70, 77--80). Further, treatment with estriol of 911 women with climacteric complaints in a five-year prospective study was not associated with endometrial or ovarian cancer (80).
5) http://www.ncbi.nlm.nih.gov/
Mayo Clin Proc. 2011 July; 86(7): 673--680.
Bioidentical Hormone Therapy -- Julia A. Files, MD, Marcia G. Ko, MD, and
Sandhya Pruthi, MD From the Division of Women's Health Internal
Medicine (J.A.F., M.G.K.), Mayo Clinic, Scottsdale, AZ; and Division of
General Internal Medicine (S.P.), Mayo Clinic, Rochester, MN.
The claim that the safety profile of bioidentical compounds is better than that of FDA-approved HT15 belies the complexities of the topic. Both CBHT and FDA-approved HT are available in various dosages, combinations, preparations, and routes of delivery that may have differing effects on risk to an individual patient.26
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
